Rhythm Pharmaceuticals has reported an 11.6% mean reduction in body mass index after 16 weeks of treatment with RM-718, offering the first meaningful clinical evidence that its experimental once-weekly injection may help patients with acquired hypothalamic obesity. The preliminary Phase 2 findings are based on only seven evaluable patients, meaning the result provides an encouraging efficacy signal rather than definitive proof that the treatment works.

The Massachusetts biotechnology company enrolled 11 patients in the open-label study. Eight remained on active treatment as of July 16, 2026, including two who had not yet completed 16 weeks, while two discontinued because of adverse events and one withdrew during the extension period.

The immediate attraction is clear: RM-718 is designed as a weekly melanocortin-4 receptor agonist that could offer a more convenient alternative to daily injectable treatment. The tougher issue is whether the magnitude of weight reduction and apparently limited skin pigmentation observed in this small group will hold up in a larger, controlled clinical trial.

What the 11.6% BMI reduction shows, and what seven patients cannot prove

Patients who reached the 16-week assessment experienced an average 11.6% reduction in body mass index from baseline. Rhythm Pharmaceuticals compared that result with a 10.1% mean reduction after 14 weeks among seven patients receiving the highest tested dose of its oral drug bivamelagon and a 10.1% reduction after 16 weeks among 64 patients treated with setmelanotide in earlier Phase 2 and Phase 3 studies.

Those comparisons suggest RM-718 may be producing biological activity consistent with other medicines that stimulate the melanocortin-4 receptor pathway. That pathway helps regulate hunger, energy expenditure and body weight but can become disrupted when the hypothalamus is damaged by a tumor, surgery, radiation, stroke or another structural injury.

Cross-trial comparisons require considerable caution. The RM-718 trial is open label, contains no placebo group in the acquired hypothalamic obesity cohort and currently has a very small evaluable population. Differences in patient characteristics, baseline body mass index, dose exposure and study procedures can make results from separate trials look more comparable than they actually are.

The seven-patient average could also change substantially as additional participants complete treatment. One unusually strong or weak response carries much more influence in a group of seven than it would in a trial containing dozens or hundreds of patients.

Rhythm Pharmaceuticals will eventually need to demonstrate that the BMI reduction is consistent across a larger population and is accompanied by clinically meaningful improvements in health, function or excessive hunger. The company will also need durability data showing whether patients continue losing weight, maintain the benefit or begin regaining weight during longer treatment.

The early result is therefore best interpreted as evidence that RM-718 appears active at the selected dosing regimen. It is not yet enough to determine whether the weekly therapy can match or outperform approved setmelanotide over a full year.

RM-718 aims to preserve weight-loss activity while limiting generalized hyperpigmentation

RM-718 is a peptide designed to activate the melanocortin-4 receptor while largely avoiding the melanocortin-1 receptor. Rhythm Pharmaceuticals believes greater receptor selectivity could preserve the effects on hunger and weight while reducing the skin hyperpigmentation associated with broader melanocortin receptor activation.

Two mild cases of hyperpigmentation occurred in the preliminary dataset, but both were limited to the injection site. Rhythm Pharmaceuticals reported no generalized hyperpigmentation, an observation that supports the drug’s design objective but remains far too limited to establish a differentiated safety profile.

The most commonly reported adverse events were injection-site reactions, nausea and vomiting. Two patients discontinued treatment because of adverse events, with one experiencing injection-site induration and another experiencing nausea.

The discontinuations matter because a weekly medicine must be tolerable enough for chronic use. Acquired hypothalamic obesity is a long-term disorder, and any treatment is likely to require sustained administration to preserve its effect.

Injection-site reactions may be manageable if they remain mild and infrequent. Persistent nausea, vomiting or hardened tissue around the injection site could become more commercially significant if those problems emerge consistently in larger studies.

The absence of generalized skin darkening is arguably the most strategically important safety observation in the initial results. Hyperpigmentation is an established effect of setmelanotide and has influenced how patients and physicians evaluate the therapy. A treatment delivering similar weight reduction with less visible pigmentation could offer a meaningful advantage, particularly for patients concerned about permanent or widespread changes in skin color.

That possibility remains hypothetical. Seven patients treated for 16 weeks cannot establish the true frequency or severity of an adverse event, and longer exposure may reveal effects not yet seen during the early treatment period.

Rhythm is building daily, oral and weekly treatments within one rare-obesity franchise

Rhythm Pharmaceuticals already markets setmelanotide as Imcivree for several rare disorders involving impaired melanocortin-4 receptor signaling. In March 2026, the United States Food and Drug Administration expanded the medicine’s approval to acquired hypothalamic obesity, making it the first approved treatment in the United States for the condition.

That approval changes the commercial role of RM-718. The weekly injection is not simply being developed to enter an untreated market; it may eventually compete with or complement Rhythm Pharmaceuticals’ own daily injectable medicine.

Imcivree gives the company an established product and commercial infrastructure, while RM-718 could offer a more convenient dosing schedule. Rhythm Pharmaceuticals is also developing bivamelagon, an oral melanocortin-4 receptor agonist, and plans to begin a pivotal Phase 3 acquired hypothalamic obesity trial by the end of 2026.

The strategy effectively gives Rhythm Pharmaceuticals three possible formats within the same therapeutic pathway: an approved daily injection, an experimental oral drug and an experimental weekly injection. That creates opportunities to serve patients with different preferences, tolerability concerns and treatment histories.

It also creates portfolio-management questions. Bivamelagon may offer the greatest convenience because it is taken orally, while RM-718 could appeal to patients who prefer infrequent injections or require the pharmacological characteristics of a peptide therapy. Imcivree has the advantage of regulatory approval, physician familiarity and demonstrated long-term efficacy.

Rhythm Pharmaceuticals may ultimately position the products by patient type rather than allowing them to compete directly. Some patients may prioritize maximum efficacy, others may prefer oral dosing, and another group may accept a weekly injection in exchange for reduced generalized hyperpigmentation.

The company is also evaluating RM-718 in Prader-Willi syndrome, with enrollment in that portion of the Phase 1/2 program expected to be completed during the second half of 2026. Success across multiple rare-obesity indications could make RM-718 a broader franchise asset rather than merely a successor to Imcivree.

Rhythm Pharmaceuticals stock shows cautious optimism after the preliminary result

Rhythm Pharmaceuticals shares were trading around $104.47 during the August 4 session, up approximately 1.6% from the previous close. The stock moved between an intraday low of $98.63 and a high of $109.51, reflecting a positive but volatile investor response to the RM-718 data and the company’s second-quarter update.

The modest net gain suggests investors found the 11.6% BMI reduction encouraging but were unwilling to assign full value to a seven-patient dataset. This interpretation is an inference from the trading pattern rather than a confirmed explanation from market participants.

Investor caution is reasonable. Rhythm Pharmaceuticals already has an approved acquired hypothalamic obesity treatment, so RM-718 must eventually demonstrate more than basic activity. Its commercial value will depend on whether weekly dosing and reduced generalized hyperpigmentation produce a sufficiently differentiated profile from Imcivree and bivamelagon.

The company’s approximately $7.1 billion market capitalization also indicates that investors already attribute substantial value to its rare-obesity franchise and pipeline. A small early-stage result may support confidence in that pipeline without dramatically altering forecasts until a larger trial provides clearer evidence.

The preliminary findings suggest RM-718 has delivered enough early clinical evidence to support further development. The 11.6% reduction strengthens the case for advancing the program, while the absence of generalized hyperpigmentation provides an initial indication that the drug may achieve the differentiation Rhythm Pharmaceuticals intended.

The dataset remains too small to establish comparative efficacy, safety or commercial superiority. The next stage must show whether the result is reproducible across more patients, whether the weight reduction continues beyond 16 weeks and whether injection-site reactions or gastrointestinal adverse events affect long-term adherence.

For now, RM-718 gives Rhythm Pharmaceuticals another credible option in its increasingly crowded internal pipeline. The weekly dosing format could become valuable, but larger controlled studies will determine whether it represents a genuine treatment advance or merely another active melanocortin-4 receptor agonist.